The Medical Advisor

It has been estimated that over 54 million adults and at least 300,000 children in the United States alone have rheumatic disease  ( American College of Rheumatology 2021 ). Since I have a massive clinical experience with RA (Rheumatoid Arthritis), I am going to use it as an example of how all autoimmune diseases can be treated. Why? Because they all have similar origins which are related to an antigen sneaking into your body and your immune system confusing it as a foreign invader. The antigen that gets into your system determines which of your body's tissues will be impacted. From the late 1980s and for the following 10 years, I treated over 3,000 patients with rheumatic illnesses, including systemic lupus erythematosus (SLE), scleroderma, polymyositis and dermatomyositis. RA has a devastating prognosis in many patients. Rheumatoid arthritis affects about 1% of our population and at least 1.4 million Americans have definite or classical rheumatoid arthritis, althoug...

Introduction: The Most Misunderstood “Vitamin” in Modern Medicine Vitamin D is everywhere. It’s recommended for: Bone health Immunity Cancer prevention Longevity Yet despite decades of research and billions spent on supplementation, a paradox remains: People with “normal” vitamin D levels still get disease. People with “low” levels sometimes remain healthy. High-dose supplementation often fails to deliver expected benefits. This contradiction has fueled viral narratives—including claims that vitamin D is misunderstood, overhyped, or even artificially constructed. The idea that “vitamin D is misunderstood” is not new. But the viral Substack piece “The Vitamin D Paradox: What They Don’t Tell You About Cholecalciferol” pushes that idea into far more controversial territory—questioning whether vitamin D itself is even “real,” whether deficiency is a testing artifact, and whether supplementation is an industrial construct. Some of these claims raise useful questions. Others collapse under...

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 Abstract Glioblastoma and other high-grade brain tumors remain among the most lethal malignancies, characterized by aggressive growth, therapeutic resistance, and near-universal recurrence despite multimodal standard-of-care treatment. In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel anticancer therapies. Among these, the antiparasitic agents ivermectin and mebendazole have attracted increasing attention due to their demonstrated anticancer activity in preclinical models, including effects on cancer stem cells, tumor metabolism, microtubule dynamics, and signaling pathways relevant to glioma progression. This article presents a compilation of over 100 real-world case reports compiled between 2019 and 2026, involving patients with glioblastoma, astrocytoma, and other intracranial tumors who incorporated ivermectin and/or mebendazole into their treatmen...